PubMed Health⌕ Search

Biomedical subjects

Egon Stenager

Publications and source records attributed to Egon Stenager.

11 recordsLinked to original sources
PubMed2005

Risk for multiple sclerosis in dizygotic and monozygotic twins.

We investigated the risks of twins for multiple sclerosis (MS). Our data are linked registers of all Danish twins and of all Danes born between 1920 and 1970 in whom MS was diagnosed before 1997. We compared differences in the risks for MS by Cox regression and standardized incidence ratios. Our analyses suggest that dizygotic twins have an approximately 60% lower risk for MS than monozygotic twins and a 20% lower risk than singletons. Monozygotic twins appear to have a somewhat higher risk for MS than singletons albeit not statistically significant. We offer no biological explanation for our findings, but suggest that either sharing fetal life with a genotypically different individual is beneficial for the immune system or that there is a linkage between the genes that influence dizygotic twinning and other genes that protect against MS.

Adult↗
PubMed2004

Trends in survival and cause of death in Danish patients with multiple sclerosis.

The Danish Multiple Sclerosis Registry contains information about all Danish patients in whom multiple sclerosis has been diagnosed since 1948. The purpose of this study was to analyse trends in survival and causes of death of these patients and to compare them with those of the general population. The study comprised all patients with onset in the period 1949-1996. All case records were validated and classified according to standardized diagnostic criteria. Data on emigration and death were obtained by record linkage to official registers. The end of follow-up was 1 January 2000 for emigration and death, and 1 January 1999 for cause-specific deaths. Standardized mortality ratios and excess death rates were calculated for various causes of death and periods after multiple sclerosis onset, and time trends in survival probability were analysed by Cox regression. The study comprised 9881 patients, of whom 4254 had died before end of follow-up. The median survival time from onset was approximately 10 years shorter for multiple sclerosis patients than for the age-matched general population, and multiple sclerosis was associated with an almost threefold increase in the risk for death. According to death certificates, more than half (56.4%) of the patients had died from multiple sclerosis. They also had excess mortality rates from other diseases, except cancer, and from accidents and suicide. The probability for survival improved significantly during the observation period. Thus, the 10-year excess mortality was almost halved in comparison with that in the middle of the 1900s.

Adult↗
PubMed2003

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.

BACKGROUND: Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies. METHODS: We measured neutralising antibodies every 12 months for up to 60 months in 541 patients with multiple sclerosis, randomly selected from all patients who started treatment with interferon beta between 1996 and 1999. Patients left the study if they changed or discontinued therapy. Antibodies were measured blindly, using antiviral neutralisation bioassays with high, medium, and low sensitivity, and with different neutralising capacities as cutoff value for definition of a neutralising-antibody-positive result. FINDINGS: Patients developed neutralising antibodies independent of age, sex, disease duration, and progression index at start of treatment. Relapse rates were significantly higher during antibody-positive periods (0.64-0.70) than they were during antibody-negative periods (0.43-0.46; p<0.03). When comparing the number of relapses in the neutralising-antibody-positive and neutralising-antibody-negative periods we found odds ratios in the range 1.51 to 1.58 (p<0.03). Time to first relapse was significantly increased by 244 days in patients who were antibody-negative at 12 months (log rank test 6.83, p=0.009). During this short-term study, presence of neutralising antibodies did not affect disease progression measured with the expanded disability status scale. INTERPRETATION: Our findings suggest that the presence of neutralising antibodies against interferon beta reduces the clinical effect of the drug. In patients who are not doing well on interferon beta, the presence of such antibodies should prompt consideration about change of treatment.

Adjuvants, Immunologic↗
PubMed2003

[Disability retirement pension for patients with syndrome diagnoses. A registry study on the basis of data from the Social Appeal Board].

INTRODUCTION: Since the early 1990s, disability retirement pension may be granted on the basis of a syndrome diagnosis. Before the pension can be granted, local public authorities collect information on health and social matters and report to The Social Appeal Board. In 1998, a new diagnostic tool was introduced based on the International Statistical Classification of Diseases and Related Health Problems (ICD-10) diagnoses. The information available in The Social Appeal Board has made it possible to study the social consequences of a syndrome diagnosis. The purpose of the study was: 1) To estimate the incidence of patients granted disability retirement pension with the diagnoses whiplash, fibromyalgia, chronic pain disorder, chronic fatigue syndromee, chronic strain syndromee, and pelvic syndromee. 2) To estimate changes in the level of pension granted to patients with syndromee diagnosis. 3) To compare differences between patients with syndromee diagnosis granted disability retirement pension to patients with other diagnoses on the following parameters: sex, civil status, income when applying for pension, and attempts of rehabilitation. 4) To estimate comorbidity of psychiatric diagnosis in patients with syndromee diagnosis. MATERIAL AND METHODS: A register study of data on pension reported to The National Social Appeal Board in the period July 1st 1998 to December 31st, 2000. RESULTS: Of all patients granted pension in the period 8.3 per cent had a syndromee diagnosis, 11 per cent of the women and 5 per cent of the men. Both the relative and the absolute number of patients with syndromee diagnosis granted a pension were increasing. Comorbidity of psychiatric disorders was 3 per cent in the group with syndromee diagnosis. More patients with syndromee diagnosis than with other diagnoses had received sickness benefits and rehabilitation when pension was granted. DISCUSSION: The large number of patients with syndromee diagnosis granted pension calls for multidisciplinary prophylactic and treatment initiatives in order to reduce the number of patients in need of public support. The results are discussed in view of the new Pension's Act which will become effective as from January 1st, 2003.

Chronic Disease↗
PubMed2003

The risk of multiple sclerosis in nurses: a population-based epidemiological study.

The incidence of multiple sclerosis (MS) in nurses during the period 1980-1996 was calculated in a nationwide study. The cohort consisted of 69,428 nurses, 2185 men and 67,243 women. Sixty (two men and 58 women) with definite MS were observed, whereas 69.3 were expected. We found no significant difference between the observed and expected number of MS cases (standardized incidence ratio = 0.87; 95% confidence interval, 0.66-1.12).

Cohort Studies↗